{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T09:00:32Z","timestamp":1781082032289,"version":"3.54.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Novo Nordisk Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s13300-026-01875-3","type":"journal-article","created":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T07:47:04Z","timestamp":1778312824000},"page":"897-910","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Semaglutide and Cardiovascular Outcomes in People with Type 2 Diabetes: A SUSTAIN-6 Post Hoc Analysis by Weight Loss Category"],"prefix":"10.1007","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9036-4486","authenticated-orcid":false,"given":"Angelo","family":"Navas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Noone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Laney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunny","family":"Sheth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanjie","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paloma","family":"Munoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Swift","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,9]]},"reference":[{"issue":"9733","key":"1875_CR1","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1016\/S0140-6736(10)60484-9","volume":"375","author":"N Sarwar","year":"2010","unstructured":"Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, et\u00a0al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375(9733):2215\u201322.","journal-title":"Lancet"},{"issue":"8","key":"1875_CR2","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.2337\/dc08-0025","volume":"31","author":"CS Fox","year":"2008","unstructured":"Fox CS, Pencina MJ, Wilson PW, Paynter NP, Vasan RS, D\u2019Agostino RB Sr. Lifetime risk of cardiovascular disease among individuals with and without diabetes stratified by obesity status in the Framingham Heart Study. Diabetes Care. 2008;31(8):1582\u20134.","journal-title":"Diabetes Care"},{"issue":"6","key":"1875_CR3","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1161\/CIRCULATIONAHA.105.548206","volume":"113","author":"DM Lloyd-Jones","year":"2006","unstructured":"Lloyd-Jones DM, Leip EP, Larson MG, D\u2019Agostino RB, Beiser A, Wilson PW, et\u00a0al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation. 2006;113(6):791\u20138.","journal-title":"Circulation"},{"issue":"19","key":"1875_CR4","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA, et\u00a0al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834\u201344.","journal-title":"N Engl J Med"},{"issue":"4","key":"1875_CR5","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et\u00a0al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311\u201322.","journal-title":"N Engl J Med"},{"issue":"10193","key":"1875_CR6","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et\u00a0al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121\u201330.","journal-title":"Lancet"},{"key":"1875_CR7","doi-asserted-by":"crossref","unstructured":"Look Ahead Research Group, Wing RR, Bolin P, Brancati FL, Bray GA, Clark JM, et\u00a0al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369(2):145\u201354.","DOI":"10.1056\/NEJMoa1212914"},{"issue":"11","key":"1875_CR8","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, Batterham RL, Calanna S, Davies M, Gaal LFV, Lingvay I, et\u00a0al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989\u20131002.","journal-title":"N Engl J Med"},{"issue":"2","key":"1875_CR9","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1001\/jama.2021.23619","volume":"327","author":"DM Rubino","year":"2022","unstructured":"Rubino DM, Greenway FL, Khalid U, O\u2019Neil PM, Rosenstock J, S\u00f8rrig R, et\u00a0al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA. 2022;327(2):138\u201350.","journal-title":"JAMA"},{"issue":"10278","key":"1875_CR10","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","volume":"397","author":"M Davies","year":"2021","unstructured":"Davies M, Faerch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, et\u00a0al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397(10278):971\u201384.","journal-title":"Lancet"},{"issue":"14","key":"1875_CR11","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1001\/jama.2021.1831","volume":"325","author":"TA Wadden","year":"2021","unstructured":"Wadden TA, Bailey TS, Billings LK, Davies M, Frias JP, Koroleva A, et\u00a0al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the step 3 randomized clinical trial. JAMA. 2021;325(14):1403\u201313.","journal-title":"JAMA"},{"issue":"4","key":"1875_CR12","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","volume":"27","author":"DJ Drucker","year":"2018","unstructured":"Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018;27(4):740\u201356.","journal-title":"Cell Metab"},{"issue":"Suppl 1","key":"1875_CR13","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/dom.13129","volume":"20","author":"MA Nauck","year":"2018","unstructured":"Nauck MA, Meier JJ. Incretin hormones: their role in health and disease. Diabetes Obes Metab. 2018;20(Suppl 1):5\u201321.","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"1875_CR14","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41591-022-01707-4","volume":"28","author":"N Sattar","year":"2022","unstructured":"Sattar N, McGuire DK, Pavo I, Weerakkody GJ, Nishiyama H, Wiese RJ, et\u00a0al. Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. Nat Med. 2022;28(3):591\u20138.","journal-title":"Nat Med"},{"issue":"Suppl 2","key":"1875_CR15","first-page":"S1","volume":"22","author":"D Ryan","year":"2014","unstructured":"Ryan D, Heaner M. Guidelines (2013) for managing overweight and obesity in adults. Preface to the full report. Obesity (Silver Spring). 2014;22(Suppl 2):S1-3.","journal-title":"Obesity (Silver Spring)"},{"issue":"2","key":"1875_CR16","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s13679-017-0262-y","volume":"6","author":"DH Ryan","year":"2017","unstructured":"Ryan DH, Yockey SR. Weight loss and improvement in comorbidity: differences at 5%, 10%, 15%, and over. Curr Obes Rep. 2017;6(2):187\u201394.","journal-title":"Curr Obes Rep"},{"issue":"7","key":"1875_CR17","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.jacc.2025.05.024","volume":"86","author":"O Gilbert","year":"2025","unstructured":"Gilbert O, Gulati M, Gluckman TJ, Kittleson MM, Rikhi R, Saseen JJ, et\u00a0al. 2025 Concise Clinical Guidance: an ACC Expert Consensus Statement on medical weight management for optimization of cardiovascular health: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2025;86(7):536\u201355.","journal-title":"J Am Coll Cardiol"},{"key":"1875_CR18","doi-asserted-by":"crossref","unstructured":"Look Ahead Research Group, Gregg EW, Jakicic JM, Blackburn G, Bloomquist P, Bray GA, et\u00a0al. Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post hoc analysis of the look AHEAD randomised clinical trial. Lancet Diabetes Endocrinol. 2016;4(11):913\u201321.","DOI":"10.1016\/S2213-8587(16)30162-0"},{"issue":"7","key":"1875_CR19","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.2337\/dc10-2415","volume":"34","author":"RR Wing","year":"2011","unstructured":"Wing RR, Lang W, Wadden TA, Safford M, Knowler WC, Bertoni AG, et\u00a0al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care. 2011;34(7):1481\u20136.","journal-title":"Diabetes Care"},{"issue":"4","key":"1875_CR20","doi-asserted-by":"publisher","DOI":"10.1097\/XCE.0000000000000346","volume":"14","author":"S Jacob","year":"2025","unstructured":"Jacob S, Eckel RH, Krentz AJ. Improved cardiovascular outcomes with glucagon-like peptide-1 receptor agonists - What is the role of weight reduction? Cardiovasc Endocrinol Metab. 2025;14(4):e00346.","journal-title":"Cardiovasc Endocrinol Metab"},{"issue":"21","key":"1875_CR21","doi-asserted-by":"publisher","first-page":"e984","DOI":"10.1161\/CIR.0000000000000973","volume":"143","author":"TM Powell-Wiley","year":"2021","unstructured":"Powell-Wiley TM, Poirier P, Burke LE, Despres JP, Gordon-Larsen P, Lavie CJ, et\u00a0al. Obesity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2021;143(21):e984\u20131010.","journal-title":"Circulation"},{"issue":"1","key":"1875_CR22","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s12933-018-0762-4","volume":"17","author":"V Ormazabal","year":"2018","unstructured":"Ormazabal V, Nair S, Elfeky O, Aguayo C, Salomon C, Zuniga FA. Association between insulin resistance and the development of cardiovascular disease. Cardiovasc Diabetol. 2018;17(1):122.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"1875_CR23","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/oby.20662","volume":"22","author":"The Look AHEAD Research Group","year":"2014","unstructured":"The Look AHEAD Research Group. Eight-year weight losses with an intensive lifestyle intervention: the look AHEAD study. Obesity (Silver Spring). 2014;22(1):5\u201313.","journal-title":"Obesity (Silver Spring)"},{"issue":"3","key":"1875_CR24","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1111\/dom.13955","volume":"22","author":"M Husain","year":"2020","unstructured":"Husain M, Bain SC, Jeppesen OK, Lingvay I, S\u00f8rrig R, Treppendahl MB, et\u00a0al. Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk. Diabetes Obes Metab. 2020;22(3):442\u201351.","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"1875_CR25","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1056\/NEJMoa1901118","volume":"381","author":"M Husain","year":"2019","unstructured":"Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, et\u00a0al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381(9):841\u201351.","journal-title":"N Engl J Med"},{"issue":"1","key":"1875_CR26","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1186\/s12933-023-02051-8","volume":"22","author":"X Tan","year":"2023","unstructured":"Tan X, Liang Y, Rajpura JR, Yedigarova L, Noone J, Xie L, et\u00a0al. Once-weekly glucagon-like peptide-1 receptor agonists vs dipeptidyl peptidase-4 inhibitors: cardiovascular effects in people with diabetes and cardiovascular disease. Cardiovasc Diabetol. 2023;22(1):319.","journal-title":"Cardiovasc Diabetol"},{"issue":"2","key":"1875_CR27","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s13300-024-01678-4","volume":"16","author":"SE Inzucchi","year":"2025","unstructured":"Inzucchi SE, Tan X, Liang Y, Yedigarova L, Xie L, de Havenon A. Cardiovascular events in adults with type\u00a02 diabetes and ASCVD initiating once-weekly semaglutide vs DPP-4is in the USA. Diabetes Ther. 2025;16(2):187\u2013203.","journal-title":"Diabetes Ther"},{"issue":"10","key":"1875_CR28","volume":"16","author":"JO Olukorode","year":"2024","unstructured":"Olukorode JO, Orimoloye DA, Nwachukwu NO, Onwuzo CN, Oloyede PO, Fayemi T, et\u00a0al. Recent advances and therapeutic benefits of glucagon-like peptide-1 (GLP-1) agonists in the management of type 2 diabetes and associated metabolic disorders. Cureus. 2024;16(10):e72080.","journal-title":"Cureus"},{"issue":"3","key":"1875_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/physiologia5030034","volume":"5","author":"M Mansoor","year":"2025","unstructured":"Mansoor M. The cardiovascular physiology of glucagon-like peptide-1 receptor agonists: from macro-level outcomes to micro-level mechanisms. Physiologia. 2025;5(3):34.","journal-title":"Physiologia"},{"key":"1875_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2024.1446468","volume":"11","author":"A Skrobucha","year":"2024","unstructured":"Skrobucha A, Pindlowski P, Krajewska N, Grabowski M, Jonik S. Anti-inflammatory effects of glucagon-like peptide-1 (GLP-1) in coronary artery disease: a comprehensive review. Front Cardiovasc Med. 2024;11:1446468.","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"1875_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-023-02096-9","volume":"23","author":"D Garcia-Vega","year":"2024","unstructured":"Garcia-Vega D, Sanchez-Lopez D, Rodriguez-Carnero G, Villar-Taibo R, Vinuela JE, Lestegas-Soto A, et\u00a0al. Semaglutide modulates prothrombotic and atherosclerotic mechanisms, associated with epicardial fat, neutrophils and endothelial cells network. Cardiovasc Diabetol. 2024;23(1):1.","journal-title":"Cardiovasc Diabetol"},{"issue":"10516","key":"1875_CR32","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1016\/S0140-6736(25)01375-3","volume":"406","author":"J Deanfield","year":"2025","unstructured":"Deanfield J, Lincoff AM, Kahn SE, Emerson SS, Lingvay I, Scirica BM, et\u00a0al. Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial. Lancet. 2025;406(10516):2257\u201368.","journal-title":"Lancet"},{"issue":"1","key":"1875_CR33","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/obr.12232","volume":"16","author":"RE Brown","year":"2015","unstructured":"Brown RE, Kuk JL. Consequences of obesity and weight loss: a devil\u2019s advocate position. Obes Rev. 2015;16(1):77\u201387.","journal-title":"Obes Rev"},{"issue":"6","key":"1875_CR34","doi-asserted-by":"publisher","DOI":"10.31083\/j.rcm2306188","volume":"23","author":"P D\u00edez-Villanueva","year":"2022","unstructured":"D\u00edez-Villanueva P, Jim\u00e9nez-M\u00e9ndez C, Bonanad C, Garc\u00eda-Blas S, P\u00e9rez-Rivera \u00c1, Allo G, et\u00a0al. Risk factors and cardiovascular disease in the elderly. Rev Cardiovasc Med. 2022;23(6):188.","journal-title":"Rev Cardiovasc Med"},{"issue":"1","key":"1875_CR35","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1001\/jama.2024.6586","volume":"332","author":"C Conte","year":"2024","unstructured":"Conte C, Hall KD, Klein S. Is weight loss-induced muscle mass loss clinically relevant? JAMA. 2024;332(1):9\u201310.","journal-title":"JAMA"},{"issue":"4","key":"1875_CR36","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1177\/87551225221092681","volume":"38","author":"A Fornes","year":"2022","unstructured":"Fornes A, Huff J, Pritchard RI, Godfrey M. Once-weekly semaglutide for weight management: a clinical review. J Pharm Technol. 2022;38(4):239\u201346.","journal-title":"J Pharm Technol"},{"key":"1875_CR37","doi-asserted-by":"crossref","unstructured":"Alexander GC, Xiao X, Dilek S, Lewis S, Deng Q, Kim M, et\u00a0al. Heterogeneity of treatment effects of glucagon-like peptide-1 receptor agonists for weight loss in adults: a systematic review and meta-analysis. JAMA Intern Med. 2026.","DOI":"10.1001\/jamainternmed.2025.8222"},{"issue":"2","key":"1875_CR38","doi-asserted-by":"publisher","first-page":"292","DOI":"10.2337\/dc24-1678","volume":"48","author":"HJ Wong","year":"2025","unstructured":"Wong HJ, Sim B, Teo YH, Teo YN, Chan MY, Yeo LLL, et\u00a0al. Efficacy of GLP-1 receptor agonists on weight loss, BMI, and waist circumference for patients with obesity or overweight: a systematic review, meta-analysis, and meta-regression of 47 randomized controlled trials. Diabetes Care. 2025;48(2):292\u2013300.","journal-title":"Diabetes Care"},{"key":"1875_CR39","doi-asserted-by":"crossref","unstructured":"Inceu GV, Craciun AE, Ciobanu DM, Berchisan A, Fodor A, Bala C, et\u00a0al. Real-world sex differences in response to treatment with glucagon-like peptide-1 receptor agonists: analysis of single-center outpatient case series. Medicina (Kaunas). 2025;61(8).","DOI":"10.3390\/medicina61081343"},{"key":"1875_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1621892","volume":"16","author":"P Milushewa","year":"2025","unstructured":"Milushewa P, Mitreva Y, Chakarova N, Tankova T, Naseva E, Petkova V. Predictive factors for HbA1c and weight loss associated with semaglutide treatment in type 2 diabetes mellitus: real-world clinical evidence. Front Endocrinol (Lausanne). 2025;16:1621892.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"12","key":"1875_CR41","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1016\/0895-4356(95)00048-8","volume":"48","author":"P Peduzzi","year":"1995","unstructured":"Peduzzi P, Concato J, Feinstein AR, Holford TR. Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates. J Clin Epidemiol. 1995;48(12):1503\u201310.","journal-title":"J Clin Epidemiol"}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-026-01875-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-026-01875-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-026-01875-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T08:22:59Z","timestamp":1781079779000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13300-026-01875-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,9]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1875"],"URL":"https:\/\/doi.org\/10.1007\/s13300-026-01875-3","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"value":"1869-6953","type":"print"},{"value":"1869-6961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,9]]},"assertion":[{"value":"26 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Angelo Navas received a UNC predoctoral fellowship funded by Novo Nordisk\u00a0Inc. Joshua Noone, Nathan Laney, Xi Tan, Yuanjie Liang, Paloma Munoz, and Caroline Swift are employees of Novo Nordisk Inc. Sunny Sheth was an employee of Novo Nordisk Inc.\u00a0at the time of this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The SUSTAIN-6 trial was conducted in accordance with the principles of the Declaration of Helsinki and Good Clinical Practice guidelines. Approval was obtained from institutional review boards or independent ethics committees at each participating site, and all participants provided written informed consent [\n                      \n                      ]. This post hoc analysis was determined to be exempt from institutional review board review by WCG IRB under 45 CFR 46.104(d)(4).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}